文献速递艾滋病与性传播感染

博茨瓦纳Tshilo Dikotla研究:宫内HIV及抗逆转录病毒暴露儿童至36月龄胰岛素敏感性持续降低

Lower Insulin Sensitivity Through 36 Months of Life With in Utero HIV and Antiretroviral Exposure in Botswana: Results From the Tshilo Dikotla Study.
PubMed 文献 · Clin Infect Dis · 2024-01-01

Tshilo Dikotla研究纳入419名儿童(287名宫内HIV/ARV暴露未感染儿[CHEU]与132名无暴露儿[CHUU]),评估出生至36月龄HOMA-IR。调整混杂后CHEU的HOMA-IR持续高于CHUU(log10 HOMA-IR平均差异0.07,P=0.02)。CHEU中按宫内ARV暴露方案或婴儿预防用AZT与NVP分组未见HOMA-IR差异。

要点

  • 宫内HIV/ARV暴露儿童从出生至36月龄胰岛素敏感性持续低于无暴露儿童。
  • CHEU与CHUU的log10 HOMA-IR平均差异为0.07(P=0.02)。
  • CHEU中不同宫内ARV方案及婴儿AZT与NVP预防组间HOMA-IR无差异。

核心结论

  • 宫内HIV/ARV暴露与生后前36个月胰岛素敏感性降低相关,提示早期代谢紊乱持续存在,可能令人担忧其远期代谢健康更差。

研究设计与样本

  • Tshilo Dikotla研究纳入感染HIV孕妇(接受替诺福韦/恩曲他滨或拉米夫定联合多替拉韦或依非韦伦)及无HIV孕妇及其活产儿。
  • 新生儿随机接受齐多夫定(AZT)或奈韦拉平(NVP)产后预防。
  • 共纳入419名儿童:287名宫内HIV/ARV暴露未感染儿(CHEU)与132名无宫内HIV/ARV暴露儿(CHUU)。
  • 于出生时及生后1、18、24、36月龄评估稳态模型胰岛素抵抗指数(HOMA-IR),采用线性混合效应模型分析。

主要发现

  • CHEU的母亲年龄更大(29.6岁 vs 25.3岁)、孕次更多(3次 vs 1次)。
  • 调整分析中,出生至36月龄CHEU的HOMA-IR持续高于CHUU,log10 HOMA-IR平均差异为0.07(P=0.02)。
  • CHEU中,按宫内ARV暴露状态比较,出生至36月龄HOMA-IR未见差异。
  • CHEU中,婴儿预防用AZT组与NVP组之间HOMA-IR未见差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are little data on changes in insulin sensitivity during the first few years of life following in utero human immunodeficiency virus (HIV) and antiretroviral (ARV) exposure. METHODS: The Tshilo Dikotla study enrolled pregnant persons with HIV (PWH) (receiving tenofovir/emtricitabine or lamivudine plus dolutegravir or efavirenz) and pregnant individuals without HIV, as well as their liveborn children. Newborns were randomized to receive either zidovudine (AZT) or nevirapine (NVP) postnatal prophylaxis. Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) was assessed at birth and 1, 18, 24, and 36 months of life. We fit linear mixed-effects models to evaluate the association between in utero HIV/ARV exposure and average HOMA-IR from birth through 36 months of life, adjusting for confounders. RESULTS: A total of 419 children were included (287 with in utero HIV/ARV exposure and uninfected [CHEU] and 132 without in utero HIV/ARV exposure [CHUU]). CHEU were born to older women (29.6 vs 25.3 years of age) with higher gravidity (3 vs 1). HOMA-IR was persistently higher in CHEU versus CHUU in adjusted analyses (mean difference of 0.07 in log10 HOMA-IR, P = .02) from birth through 36 months of life. Among CHEU, no differences in HOMA-IR were observed from birth through 36 months by in utero ARV exposure status or between AZT and NVP infant prophylaxis arms. CONCLUSIONS: In utero HIV/ARV exposure was associated with lower insulin sensitivity throughout the first 36 months of life, indicating persistent early life metabolic disturbances which may raise concern for poorer metabolic health later in life.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Jao J, Bonner LB, Dobinda K, et al. Lower Insulin Sensitivity Through 36 Months of Life With in Utero HIV and Antiretroviral Exposure in Botswana: Results From the Tshilo Dikotla Study. Clin Infect Dis. 2024. PMID: 38531012. doi:10.1093/cid/ciae088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。